cagrilintide fda vs Tirzepatide Compared Cagrilintide (AM833) - Phoenix Peptide

Cagrilintide the Phase 2 monotherapy trial studied once-weekly doses of 0.3, 0.6, 1.2, 2.4, and 4.5 mg with a dose-escalation period

doi:10.1056/NEJMoa2502082

[4] In the SURMOUNT-1 obesity trial, a 72-week placebo-controlled study in 2,539 adults with obesity (without diabetes), mean weight change was 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses versus 3.1% for placebo

Tirzepatide carries an FDA boxed warning for thyroid C-cell tumors plus warnings for pancreatitis, gallbladder disease, and hypoglycemia with insulin secretagogues

Different indications

Its designation permits its use exclusively for in vitro testing and laboratory experimentation